CCM
HAE icon

Chilton Capital Management’s Haemonetics HAE Stock Holding History

Chilton Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34
Closed -$2.73K – 614
2024
Q3 		$2.73K Hold
34
– – ﹤0.01% 587
2024
Q2 		$2.81K Buy
+34
New +$2.99K ﹤0.01% 552

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Chilton Capital Management's HAE Position: Q4 2024 in Review

Chilton Capital Management sold out of Haemonetics (HAE) in Q4 2024, closing a stake of 34 shares — an estimated $2.73K sold.

Chilton Capital Management first reported a position in HAE in Q2 2024 and held it in 2 quarters. The position peaked at $2.81K in Q2 2024. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Chilton Capital Management reported no remaining Haemonetics position as of Q4 2024 after selling out during the quarter.
  • Chilton Capital Management sold 34 Haemonetics shares in Q4 2024, an estimated $2.73K.
  • Chilton Capital Management first reported a position in Haemonetics in Q2 2024 and held it in 2 quarters.
  • Chilton Capital Management's Haemonetics position peaked at $2.81K in Q2 2024.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Chilton Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.